If shares hit our buy price, our target potential upside is 34%-63% in the next 3-6 months.
This ‘Dream Stock’ Looks Slightly Overvalued
by •
While the company has made progress and boasts innovation, the ongoing losses and uncertain path to profitability justify a cautious stance.
Upgrades and Downgrades for Monday, 9/16
by •
Here are today’s upgrades and downgrades: Oracle, Nestle, Southern Company, Ally Financial, Synchrony, Colgate-Palmolive, BioNTech and more.
This Warren Buffett Stock Looks Ridiculously Cheap
by •
Its balance sheet is strong and it looks undervalued relative to its growth potential.
4 Mega-Cap Tech Stocks to Buy Ahead of Fed’s September Rate Cut
by •
These names have strong potential for 2024.
Do NOT Panic-Sell Your Positions
by •
Unless you plan to retire and sell your securities in the next month, it’s best to stand pat and ride out the volatility.
Trade This Stock for a 19-37%% Potential Return in the Next 3-6 Months
by •
It looks poised for a surge in the short-term.
Upgrades and Downgrades for Friday, 9/13
by •
Here are today’s upgrades and downgrades: Moderna, AstraZeneca, Alexandria Real Estate, Federal Realty Trust, Roche, Voya Financial and more.
This Dominant Stock is Likely Headed Much Higher in the Months Ahead
by •
Investors who act could see fantastic returns.
1 Unstoppable Growth Stock to Buy Right Now
by •
The company’s prospects are strong due to its competitive edge and long runway for growth in its industry.